Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
Pipeline Monitor
Pfizer scores pain win
Pfizer's new tamper proof opioid Troxyca ER has been approved in the US for the management of severe pain for which alternative treatment options are inadequate.
PBAC Agenda
PBAC faces massive list for November meeting
The agenda for the November PBAC meeeting presents the committee with a massive list of submissions, totalling 59 in all, 25 of which are major submissions.
Approvals Action
Another Indian major targets Aust
Indian generics and API manufacturer Alembic Pharmaceuticals is beginning to build a portfolio in Australia.
PBAC Outcomes
July PBAC produces controversial results
Outcomes from the July meeting of the PBAC have emerged as the most controversial in some time. Our complete list, sorted by indication, is here.